Login to Your Account



No chin-scratcher: Kythera takes back global ATX-101 rights from Bayer

By Marie Powers
Staff Writer

Tuesday, March 11, 2014
Five months after an upsized follow-on offering brought in $120 million and in the midst of preparing its new drug application (NDA) to the FDA for ATX-101, Kythera Biopharmaceuticals Inc. pulled off a crafty reacquisition of global rights for the aesthetic candidate from Bayer Healthcare’s Consumer Care Division, a unit of Bayer AG, of Leverkusen, Germany.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription